Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 31 to 40 of 2545

TitleReference numberPublishedLast updated
Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)TA1132
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1129
Obinutuzumab with mycophenolate mofetil for treating lupus nephritisTA1131
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancerTA1130
Pulmonary artery pressure technologies for remote monitoring of chronic heart failureHTG769
Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancerTA1127
Targeted-release budesonide for treating primary IgA nephropathyTA1128
Digital technologies to support self-management of COPD: early value assessmentHTG736
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapyTA1126
Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)TA1124

Results per page

  1. 10
  2. 25
  3. 50
  4. All